{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:03:05Z","timestamp":1793592185890,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017759","name":"Childhood Arthritis and Rheumatology Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017759","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.hoc.2025.02.004","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T13:33:57Z","timestamp":1742909637000},"page":"597-615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Macrophage Activation Syndrome"],"prefix":"10.1016","volume":"39","author":[{"given":"Sonia","family":"Iosim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0242-4029","authenticated-orcid":false,"given":"Lauren A.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hoc.2025.02.004_bib1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S0022-3476(83)80704-5","article-title":"Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis","volume":"103","author":"Silverman","year":"1983","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0022-3476(70)80324-9","article-title":"Hepatic involvement in juvenile rheumatoid arthritis","volume":"77","author":"Schaller","year":"1970","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.004_bib3","first-page":"673","article-title":"Hepatic abnormalities in adult onset Still\u2019s disease","volume":"6","author":"Esdaile","year":"1979","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.004_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-3476(85)80072-X","article-title":"Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection","volume":"106","author":"Hadchouel","year":"1985","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.004_bib5","first-page":"451","article-title":"Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases","volume":"11","author":"Stephan","year":"1993","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.hoc.2025.02.004_bib6","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/art.38793","article-title":"Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis","volume":"66","author":"Kaufman","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.hoc.2025.02.004_bib7","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/infdis\/jiv550","article-title":"Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza","volume":"213","author":"Schulert","year":"2016","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.004_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"15","key":"10.1016\/j.hoc.2025.02.004_bib9","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.02.004_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"10.1016\/j.hoc.2025.02.004_bib11","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2025.02.004_bib12","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","article-title":"IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.hoc.2025.02.004_bib14","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/art.1780340912","article-title":"Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis","volume":"34","author":"de Benedetti","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"160","author":"Shimizu","year":"2015","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.004_bib16","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.004_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/adc.85.5.421","article-title":"Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders","volume":"85","author":"Sawhney","year":"2001","journal-title":"Arch Dis Child"},{"issue":"11","key":"10.1016\/j.hoc.2025.02.004_bib18","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.hoc.2025.02.004_bib20","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s10067-015-2923-0","article-title":"Macrophage activation syndrome in the course of monogenic autoinflammatory disorders","volume":"34","author":"Rigante","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib21","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1542\/peds.2010-3639","article-title":"Mevalonate kinase deficiency: a survey of 50 patients","volume":"128","author":"Bader-Meunier","year":"2011","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.004_bib22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/acr.20418","article-title":"Macrophage activation syndrome revealing familial Mediterranean fever","volume":"63","author":"Rossi-Semerano","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"12","key":"10.1016\/j.hoc.2025.02.004_bib23","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1084\/jem.20190147","article-title":"A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function","volume":"216","author":"Lam","year":"2019","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.hoc.2025.02.004_bib24","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome","volume":"46","author":"Canna","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.004_bib25","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition","volume":"139","author":"Canna","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.hoc.2025.02.004_bib26","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/ng.3066","article-title":"Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation","volume":"46","author":"Romberg","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MD.0000000000000021","article-title":"Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients","volume":"93","author":"Gerfaud-Valentin","year":"2014","journal-title":"Medicine (Baltim)"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.004_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000451","article-title":"Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients","volume":"94","author":"Bae","year":"2015","journal-title":"Medicine (Baltim)"},{"issue":"8","key":"10.1016\/j.hoc.2025.02.004_bib29","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s10067-020-04949-0","article-title":"Macrophage activation syndrome associated with adult-onset Still\u2019s disease: a multicenter retrospective analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.004_bib30","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.40417","article-title":"Features, treatment, and outcomes of macrophage activation syndrome in childhood-onset systemic lupus erythematosus","volume":"70","author":"Borgia","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.hoc.2025.02.004_bib31","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.autrev.2017.05.010","article-title":"Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 103 episodes in 89 adult patients","volume":"16","author":"Gavand","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"5446","key":"10.1016\/j.hoc.2025.02.004_bib32","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1126\/science.286.5446.1957","article-title":"Perforin gene defects in familial hemophagocytic lymphohistiocytosis","volume":"286","author":"Stepp","year":"1999","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.004_bib33","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0092-8674(03)00855-9","article-title":"Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3)","volume":"115","author":"Feldmann","year":"2003","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.004_bib34","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ajhg.2009.09.005","article-title":"Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11","volume":"85","author":"zur Stadt","year":"2009","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.004_bib35","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/hmg\/ddi076","article-title":"Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11","volume":"14","author":"zur Stadt","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.hoc.2025.02.004_bib36","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.02.004_bib37","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.V78.11.2918.2918","article-title":"Hypercytokinemia in familial hemophagocytic lymphohistiocytosis","volume":"78","author":"Henter","year":"1991","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.02.004_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1084\/jem.20140964","article-title":"Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time","volume":"212","author":"Jenkins","year":"2015","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.hoc.2025.02.004_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41435-020-0098-4","article-title":"The genetics of macrophage activation syndrome","volume":"21","author":"Schulert","year":"2020","journal-title":"Genes Immun"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/MOP.0b013e32834ec9c1","article-title":"Hemophagocytic lymphohistiocytosis: updates and evolving concepts","volume":"24","author":"Risma","year":"2012","journal-title":"Curr Opin Pediatr"},{"issue":"22","key":"10.1016\/j.hoc.2025.02.004_bib41","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1182\/blood-2011-07-370148","article-title":"Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.02.004_bib42","first-page":"1566","article-title":"Enrichment of rare variants of hemophagocytic lymphohistiocytosis genes in systemic juvenile idiopathic arthritis","volume":"76","author":"Correia Marques","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.hoc.2025.02.004_bib43","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/art.39295","article-title":"Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome","volume":"67","author":"Cifaldi","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.hoc.2025.02.004_bib44","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1067\/mpd.2003.110","article-title":"Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome","volume":"142","author":"Grom","year":"2003","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib45","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar1453","article-title":"Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome","volume":"7","author":"Villanueva","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.004_bib46","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.004_bib47","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jaci.2017.07.021","article-title":"Neutralization of IFN-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome","volume":"141","author":"Prencipe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.hoc.2025.02.004_bib48","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2019.03.018","article-title":"Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome","volume":"119","author":"Mizuta","year":"2019","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib49","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.004_bib50","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"10.1016\/j.hoc.2025.02.004_bib51","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2025.02.004_bib52","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/S2665-9913(21)00115-6","article-title":"Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study","volume":"3","author":"Kessel","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.hoc.2025.02.004_bib53","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.hoc.2025.02.004_bib54","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I","article-title":"Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still\u2019s disease","volume":"44","author":"Kawaguchi","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1074-7613(00)80013-8","article-title":"Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response","volume":"10","author":"Novick","year":"1999","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.004_bib56","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/BOR.0000000000000526","article-title":"Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment","volume":"30","author":"Yasin","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","article-title":"Biological and clinical roles of IL-18 in inflammatory diseases","volume":"20","author":"Landy","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"6552","key":"10.1016\/j.hoc.2025.02.004_bib58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/378088a0","article-title":"Cloning of a new cytokine that induces IFN-gamma production by T cells","volume":"378","author":"Okamura","year":"1995","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.hoc.2025.02.004_bib59","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/art.42636","article-title":"The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS)","volume":"75","author":"Shakoory","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib60","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"10.1016\/j.hoc.2025.02.004_bib61","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam","year":"2011","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2025.02.004_bib62","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Rosee","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2025.02.004_bib63","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2014-10-602607","article-title":"Marked hyperferritinemia does not predict for HLH in the adult population","volume":"125","author":"Schram","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.02.004_bib64","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1784529","article-title":"Evaluation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis: a single center experience","volume":"2022","author":"Hoeg","year":"2022","journal-title":"Int J Rheumatol"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib65","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2665-9913(23)00273-4","article-title":"Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH across Speciality Collaboration (HiHASC) consensus guideline","volume":"6","author":"Cox","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.hoc.2025.02.004_bib66","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/acr.23482","article-title":"Validation of classification criteria of macrophage activation syndrome in Japanese patients with systemic juvenile idiopathic arthritis","volume":"70","author":"Shimizu","year":"2018","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000161","article-title":"Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"2","author":"Ravelli","year":"2016","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12969-019-0309-6","article-title":"Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome","volume":"17","author":"Halyabar","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"issue":"3","key":"10.1016\/j.hoc.2025.02.004_bib69","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1365-2249.2003.02237.x","article-title":"Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis","volume":"133","author":"Takada","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"19","key":"10.1016\/j.hoc.2025.02.004_bib70","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib71","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2019-216030","article-title":"Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"79","author":"Lee","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.hoc.2025.02.004_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108252","article-title":"Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"208","author":"Takakura","year":"2019","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.004_bib73","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/bloodadvances.2018027417","article-title":"Central nervous system-restricted familial hemophagocytic lymphohistiocytosis responds to hematopoietic cell transplantation","volume":"3","author":"Li","year":"2019","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.hoc.2025.02.004_bib74","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165616","article-title":"Type I interferon signature and cycling lymphocytes in macrophage activation syndrome","volume":"133","author":"Huang","year":"2023","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.hoc.2025.02.004_bib75","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1182\/blood.2021013549","article-title":"Expansion of CD4dimCD8+ T cells characterizes macrophage activation syndrome and other secondary HLH","volume":"140","author":"De Matteis","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.02.004_bib76","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/rheumatology\/40.11.1285","article-title":"Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients","volume":"40","author":"Stephan","year":"2001","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib77","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3476(96)70408-0","article-title":"Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine","volume":"128","author":"Ravelli","year":"1996","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.004_bib78","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1189\/jlb.3VMA0315-078R","article-title":"Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state","volume":"98","author":"Kozicky","year":"2015","journal-title":"J Leukoc Biol"},{"issue":"7","key":"10.1016\/j.hoc.2025.02.004_bib79","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.4049\/jimmunol.161.7.3781","article-title":"Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway","volume":"161","author":"Prasad","year":"1998","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.immuni.2006.11.010","article-title":"FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin","volume":"26","author":"Park-Min","year":"2007","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib81","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ajh.1141","article-title":"Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes","volume":"68","author":"Emmenegger","year":"2001","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.hoc.2025.02.004_bib82","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","article-title":"Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis","volume":"64","author":"DeWitt","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.004_bib83","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.hoc.2025.02.004_bib84","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Ter","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib85","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib86","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.41103","article-title":"Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis","volume":"72","author":"Eloseily","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib87","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib88","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13054-018-2012-2","article-title":"Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review","volume":"22","author":"Neel","year":"2018","journal-title":"Crit Care"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.004_bib89","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.semarthrit.2015.11.002","article-title":"Macrophage activation syndrome complicating adult onset Still\u2019s disease: a single center case series and comparison with literature","volume":"45","author":"Lenert","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib90","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/rheumatology\/keae391","article-title":"Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project","volume":"64","author":"Baldo","year":"2025","journal-title":"Rheumatology"},{"issue":"23","key":"10.1016\/j.hoc.2025.02.004_bib91","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/jama.1994.03510470040032","article-title":"Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group","volume":"271","author":"Fisher","year":"1994","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib92","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1016\/j.hoc.2025.02.004_bib93","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.hoc.2025.02.004_bib94","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/ard-2023-224123","article-title":"The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS)","volume":"82","author":"Shakoory","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.hoc.2025.02.004_bib95","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10875-017-0439-x","article-title":"A personalized diagnostic and treatment approach for macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in adults","volume":"37","author":"Kumar","year":"2017","journal-title":"J Clin Immunol"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.004_bib96","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PCC.0000000000000078","article-title":"Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction\/macrophage activating syndrome in critically ill children","volume":"15","author":"Rajasekaran","year":"2014","journal-title":"Pediatr Crit Care Med"},{"issue":"9","key":"10.1016\/j.hoc.2025.02.004_bib97","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/0885066617711386","article-title":"Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis","volume":"34","author":"Wohlfarth","year":"2019","journal-title":"J Intensive Care Med"},{"issue":"3","key":"10.1016\/j.hoc.2025.02.004_bib98","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.hoc.2025.02.004_bib99","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.004_bib100","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.004_bib101","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.19803","article-title":"Ruxolitinib-based regimen in children with autoimmune disease or autoinflammatory disease-related haemophagocytic lymphohistiocytosis","volume":"206","author":"Fang","year":"2024","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.hoc.2025.02.004_bib102","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.004_bib103","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keac440","article-title":"JAK inhibitors in difficult-to-treat adult-onset Still\u2019s disease and systemic-onset juvenile idiopathic arthritis","volume":"62","author":"Gillard","year":"2023","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.004_bib104","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41390-021-01891-y","article-title":"A specialized multi-disciplinary care program for children with sepsis and multiple organ dysfunction-associated immune dysregulation","volume":"91","author":"Swigart","year":"2022","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1016\/j.hoc.2025.02.004_bib105","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1097\/MPH.0000000000002602","article-title":"Pediatric hemophagocytic lymphohistiocytosis: formation of an interdisciplinary HLH working group at a single institution","volume":"45","author":"Watts","year":"2023","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.hoc.2025.02.004_bib106","doi-asserted-by":"crossref","first-page":"1519955","DOI":"10.3389\/fimmu.2025.1519955","article-title":"Multidisciplinary approach to treating complex immune dysregulation disorders: an adaptive model for institutional implementation","volume":"16","author":"Henderson","year":"2025","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.hoc.2025.02.004_bib107","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3899\/jrheum.211219","article-title":"An evidence-based guideline improves outcomes for patients with hemophagocytic lymphohistiocytosis and macrophage activation syndrome","volume":"49","author":"Taylor","year":"2022","journal-title":"J Rheumatol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882500019X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882500019X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T11:54:50Z","timestamp":1748174090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985882500019X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S088985882500019X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.02.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macrophage Activation Syndrome","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}